{"downloaded": true, "htmlmade": false, "full": {"id": "29938772", "source": "MED", "pmid": "29938772", "pmcid": "PMC6055619", "fullTextIdList": {"fullTextId": "PMC6055619"}, "doi": "10.1111/bjh.15394", "title": "Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.", "authorString": "Richardson PG, Hofmeister CC, Rosenbaum CA, Htut M, Vesole DH, Berdeja JG, Liedtke M, Chari A, Smith SD, Lebovic D, Raje N, Byrne C, Liao E, Gupta N, Bacco AD, Estevam J, Berg D, Baz R.", "authorList": {"author": [{"fullName": "Richardson PG", "firstName": "Paul G", "lastName": "Richardson", "initials": "PG", "authorId": {"@type": "ORCID", "#text": "0000-0002-7426-8865"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Dana-Farber Cancer Institute, Boston, MA, USA."}}}, {"fullName": "Hofmeister CC", "firstName": "Craig C", "lastName": "Hofmeister", "initials": "CC", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Ohio State University, Columbus, OH, USA."}}}, {"fullName": "Rosenbaum CA", "firstName": "Cara A", "lastName": "Rosenbaum", "initials": "CA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology/Oncology, University of Chicago Medicine, Chicago, IL, USA."}}}, {"fullName": "Htut M", "firstName": "Myo", "lastName": "Htut", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology and Stem Cell Transplant, City of Hope National Medical Center Duarte, Duarte, CA, USA."}}}, {"fullName": "Vesole DH", "firstName": "David H", "lastName": "Vesole", "initials": "DH", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA."}}}, {"fullName": "Berdeja JG", "firstName": "Jesus G", "lastName": "Berdeja", "initials": "JG", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Sarah Cannon Research Institute, Nashville, TN, USA."}}}, {"fullName": "Liedtke M", "firstName": "Michaela", "lastName": "Liedtke", "initials": "M", "authorId": {"@type": "ORCID", "#text": "0000-0001-8945-5850"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Stanford Comprehensive Cancer Center, Stanford, CA, USA."}}}, {"fullName": "Chari A", "firstName": "Ajai", "lastName": "Chari", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Mount Sinai School of Medicine Ruttenberg Treatment Center, New York, NY, USA."}}}, {"fullName": "Smith SD", "firstName": "Stephen D", "lastName": "Smith", "initials": "SD", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA."}}}, {"fullName": "Lebovic D", "firstName": "Daniel", "lastName": "Lebovic", "initials": "D", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University of Michigan Cancer Center, Ann Arbor, MI, USA."}}}, {"fullName": "Raje N", "firstName": "Noopur", "lastName": "Raje", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Massachusetts General Hospital, Boston, MA, USA."}}}, {"fullName": "Byrne C", "firstName": "Catriona", "lastName": "Byrne", "initials": "C", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Millennium Pharmaceuticals Inc., Cambridge, MA, USA."}}}, {"fullName": "Liao E", "firstName": "Eileen", "lastName": "Liao", "initials": "E", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Millennium Pharmaceuticals Inc., Cambridge, MA, USA."}}}, {"fullName": "Gupta N", "firstName": "Neeraj", "lastName": "Gupta", "initials": "N", "authorId": {"@type": "ORCID", "#text": "0000-0002-5500-5218"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Millennium Pharmaceuticals Inc., Cambridge, MA, USA."}}}, {"fullName": "Bacco AD", "firstName": "Alessandra Di", "lastName": "Bacco", "initials": "AD", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Millennium Pharmaceuticals Inc., Cambridge, MA, USA."}}}, {"fullName": "Estevam J", "firstName": "Jose", "lastName": "Estevam", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Millennium Pharmaceuticals Inc., Cambridge, MA, USA."}}}, {"fullName": "Berg D", "firstName": "Deborah", "lastName": "Berg", "initials": "D", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Millennium Pharmaceuticals Inc., Cambridge, MA, USA."}}}, {"fullName": "Baz R", "firstName": "Rachid", "lastName": "Baz", "initials": "R", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA."}}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0001-8945-5850"}, {"@type": "ORCID", "#text": "0000-0002-5500-5218"}, {"@type": "ORCID", "#text": "0000-0002-7426-8865"}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "2", "volume": "182", "journalIssueId": "2704517", "dateOfPublication": "2018 Jul", "monthOfPublication": "7", "yearOfPublication": "2018", "printPublicationDate": "2018-07-01", "journal": {"title": "British journal of haematology", "ISOAbbreviation": "Br J Haematol", "medlineAbbreviation": "Br J Haematol", "NLMid": "0372544", "ISSN": "0007-1048", "ESSN": "1365-2141"}}, "pubYear": "2018", "pageInfo": "231-244", "abstractText": "Weekly ixazomib with lenalidomide-dexamethasone (Rd) is feasible and has shown activity in newly diagnosed multiple myeloma (NDMM) patients. This phase 1/2 study (NCT01383928) evaluated the recommended phase 2 dose (RP2D), pharmacokinetics, safety and efficacy of twice-weekly ixazomib plus Rd in NDMM; 64 patients were enrolled across both phases. Patients received twice-weekly oral ixazomib 3\u00b70 or 3\u00b77\u00a0mg plus lenalidomide 25\u00a0mg and dexamethasone 20\u00a0mg (10\u00a0mg in cycles 9-16) for up to sixteen 21-day cycles, followed by maintenance with twice-weekly ixazomib alone. No dose-limiting toxicities were reported in cycle 1; the RP2D was 3\u00b70\u00a0mg based on overall tolerability across multiple cycles. In 62 evaluable patients, the confirmed overall response rate was 94% (68% \u2265very good partial response; 24% complete response). Median progression-free survival was 24\u00b79\u00a0months. Responses (median duration 36\u00b79\u00a0months for patients receiving the RP2D) deepened during treatment. Grade 3 drug-related adverse events (AEs) occurred in 64% of patients, including: rash, 13%; peripheral neuropathy, 8%; hyperglycaemia, 8%. There were no grade 4 drug-related AEs. Thirteen patients discontinued due to AEs. Twice-weekly ixazomib-Rd offers substantial activity with promising long-term outcomes in NDMM patients but may be associated with greater toxicity compared with weekly ixazomib-Rd in this setting.", "affiliation": "Dana-Farber Cancer Institute, Boston, MA, USA.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Clinical Trial, Phase I", "Journal Article"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Multiple Myeloma", "meshQualifierList": {"meshQualifier": {"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Boron Compounds", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Dexamethasone", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Glycine", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "AA", "qualifierName": "analogs & derivatives", "majorTopic_YN": "N"}, {"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Combined Chemotherapy Protocols", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Disease-Free Survival"}, {"majorTopic_YN": "N", "descriptorName": "Treatment Outcome"}, {"majorTopic_YN": "N", "descriptorName": "Administration, Oral"}, {"majorTopic_YN": "N", "descriptorName": "Drug Administration Schedule"}, {"majorTopic_YN": "N", "descriptorName": "Dose-Response Relationship, Drug"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Aged, 80 and over"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Lenalidomide", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}]}}]}, "keywordList": {"keyword": ["Multiple myeloma", "Oral", "Newly Diagnosed", "Ixazomib", "Twice-weekly"]}, "chemicalList": {"chemical": [{"name": "Boron Compounds", "registryNumber": "0"}, {"name": "Glycine", "registryNumber": "TE7660XO1C"}, {"name": "Dexamethasone", "registryNumber": "7S5I7G3JQL"}, {"name": "lenalidomide", "registryNumber": "F0P408N6V4"}, {"name": "ixazomib", "registryNumber": "71050168A2"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1111/bjh.15394"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6055619"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6055619?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "11", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by-nc", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-06-03", "dateOfCreation": "2018-06-26", "firstIndexDate": "2018-06-25", "fullTextReceivedDate": "2020-07-11", "dateOfRevision": "2019-06-03", "electronicPublicationDate": "2018-06-25", "firstPublicationDate": "2018-06-25"}, "htmllinks": "https://europepmc.org/articles/PMC6055619", "abstract": "Weekly ixazomib with lenalidomide-dexamethasone (Rd) is feasible and has shown activity in newly diagnosed multiple myeloma (NDMM) patients. This phase 1/2 study (NCT01383928) evaluated the recommended phase 2 dose (RP2D), pharmacokinetics, safety and efficacy of twice-weekly ixazomib plus Rd in NDMM; 64 patients were enrolled across both phases. Patients received twice-weekly oral ixazomib 3\u00b70 or 3\u00b77\u00a0mg plus lenalidomide 25\u00a0mg and dexamethasone 20\u00a0mg (10\u00a0mg in cycles 9-16) for up to sixteen 21-day cycles, followed by maintenance with twice-weekly ixazomib alone. No dose-limiting toxicities were reported in cycle 1; the RP2D was 3\u00b70\u00a0mg based on overall tolerability across multiple cycles. In 62 evaluable patients, the confirmed overall response rate was 94% (68% \u2265very good partial response; 24% complete response). Median progression-free survival was 24\u00b79\u00a0months. Responses (median duration 36\u00b79\u00a0months for patients receiving the RP2D) deepened during treatment. Grade 3 drug-related adverse events (AEs) occurred in 64% of patients, including: rash, 13%; peripheral neuropathy, 8%; hyperglycaemia, 8%. There were no grade 4 drug-related AEs. Thirteen patients discontinued due to AEs. Twice-weekly ixazomib-Rd offers substantial activity with promising long-term outcomes in NDMM patients but may be associated with greater toxicity compared with weekly ixazomib-Rd in this setting.", "Keywords": ["Multiple myeloma", "Oral", "Newly Diagnosed", "Ixazomib", "Twice-weekly"], "pdflinks": "https://europepmc.org/articles/PMC6055619?pdf=render", "journaltitle": "British journal of haematology", "authorinfo": ["Richardson PG", "Hofmeister CC", "Rosenbaum CA", "Htut M", "Vesole DH", "Berdeja JG", "Liedtke M", "Chari A", "Smith SD", "Lebovic D", "Raje N", "Byrne C", "Liao E", "Gupta N", "Bacco AD", "Estevam J", "Berg D", "Baz R"], "title": "Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma."}